Related Experiment Video
Updated: May 5, 2026

Enrichment and Detection of Clostridium perfringens Toxinotypes in Retail Food Samples
Published on: October 18, 2019
Multiple Sclerosis and Clostridium perfringens Epsilon Toxin: Is There a Relationship?
André Huss1, Franziska Bachhuber1, Cécile Feraudet-Tarisse2
1Department of Neurology, University Hospital Ulm, 89081 Ulm, Germany.
Abstract:
Recent research has suggested a link between multiple sclerosis and the gut microbiota. This prospective pilot study aimed to investigate the composition of the gut microbiota in MS patients, the presence of Clostridium perfringens epsilon toxin in the serum of MS patients, and the influence of disease-modifying drugs (DMDs) on epsilon toxin levels and on the microbiota. Epsilon toxin levels in blood were investigated by two methods, a qualitative ELISA and a highly sensitive quantitative ELISA. Neither epsilon toxin nor antibodies against it were detected in the analyzed serum samples. 16S ribosomal RNA sequencing was applied to obtain insights into the composition of the gut microbiota of MS patients. No significant differences in the quantity, diversity, and the relative abundance of fecal microbiota were observed in the gut microbiota of MS patients receiving various DMDs, including teriflunomide, natalizumab, ocrelizumab, and fingolimod, or no therapy. The present study did not provide evidence supporting the hypothesis of a causal relationship between Clostridium perfringens epsilon toxin and multiple sclerosis.
Insights
This study found no evidence linking Clostridium perfringens epsilon toxin to multiple sclerosis (MS). Gut microbiota composition and diversity in MS patients were not significantly affected by disease-modifying drugs.
Area of Science:
- Neurology
- Microbiology
- Immunology
Background:
- Emerging research suggests a connection between the gut microbiota and multiple sclerosis (MS).
- The role of Clostridium perfringens epsilon toxin in MS pathogenesis remains unclear.
Purpose of the Study:
- To investigate gut microbiota composition in MS patients.
- To determine the presence of Clostridium perfringens epsilon toxin in MS patients' serum.
- To assess the impact of disease-modifying drugs (DMDs) on epsilon toxin levels and gut microbiota.
Main Methods:
- Prospective pilot study design.
- Qualitative and quantitative ELISA for epsilon toxin detection.
- 16S ribosomal RNA sequencing for gut microbiota analysis.
Main Results:
- Clostridium perfringens epsilon toxin and its antibodies were not detected in MS patient serum.
- No significant differences in gut microbiota quantity, diversity, or relative abundance were found among MS patients on different DMDs or no therapy.
Conclusions:
- The study did not find evidence to support a causal link between Clostridium perfringens epsilon toxin and multiple sclerosis.
- Disease-modifying drugs did not significantly alter the gut microbiota composition in the studied MS patients.
More Related Videos
08:17Author Spotlight: Unveiling the Pathway Linking Obesity to Autoimmune Inflammation in Multiple Sclerosis
Published on: February 23, 2024
05:44Author Spotlight: Creating a Versatile Experimental Autoimmune Encephalomyelitis Model Relevant for Both Male and Female Mice
Published on: October 13, 2023
Related Concept Videos
Bacterial Toxins
Diphtheria
Bacterial Gastroenteritis
Encephalitis ll: Pathophysiology
Multiple Sclerosis l: Introduction
Inflammatory Bowel Disease III: Crohn's Disease